Enovis CORP (ENOV): what the price requires

At today's price, Enovis CORP (ENOV) is priced for -1.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ENOV

Headline

FieldValue
TickerENOV
CompanyEnovis CORP
Current price$26.24/sh
CompositionPrevention & Recovery (P&R) 51% / Reconstructive (Recon) 49%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed2.2%
Operating margin (mid-cycle)6.9%
Margin compression implied-4.7pp
Trailing margin (depressed year)-27.2%
Implied growth-1.9%
Multiple paid17x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 10, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7.4% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7pp.

Reconcile: at the x-ray's 9.3% required return this reads ~10.5%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.31σ
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and relative-multiple value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.07x2expensive
Earnings—0—
Relative0.17x1justifies
Growth—0—

Families that justify the price: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.1%); the inversion above states its own rate.

Per-Model Detail (n=3)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$159.010.17xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$25.771.02xyesReference only (book value floor): BV/sh $25.77, ROE negative
Two-Stage Excess ReturnAsset$23.191.13xyesReference only (book value with convergence): BV/sh $25.77, ROE converges to ke
Discounted Future Market CapGrowth$20.961.25xnoRev $2.3B, growth 6% (input: historical growth; tapered), Terminal P/S: 0.6x / 0.7x / 0.8x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings$0.012624.00xyesFCF $35.9M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.012624.00xyesSBC-adj FCF $0.00B (FCF $0.04B − SBC $0.03B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$0.9328.22xyesBV $25.77 × (ROIC 0.2% / WACC 5.1%) (excluded from median)
P/Sales SectorRelative$159.010.17xnoRevenue $2.28B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.3b
Net debt / NOPAT (after-tax)10.51x
Net debt / operating income (pre-tax)8.30x
Interest coverage4.3x
Share count CAGR (dilution)1.3%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 6.9%); the trailing year was depressed.

Bullet Takeaways

Bull Case

The cleanest read on Enovis is its capital-allocation picture, because the stock is a deleveraging story dressed as an orthopedics company. Management has bet the business on building a scaled musculoskeletal franchise, and the defining move was the LimaCorporate acquisition, which added a surgeon-focused implant portfolio to the existing Reconstructive and Prevention-and-Recovery segments. The cost of that bet shows up as debt and as amortization, but the cash-generation commitment is the tell: management reaffirmed free-cash-flow conversion above 25 percent for 2026 even against tariff and Middle East headwinds. A company throwing off that much cash relative to earnings, while trading below book value, is set up to deleverage its way to a higher equity value if it executes.

The operating trajectory supports the plan. First-quarter 2026 revenue rose about 5 percent to $589 million, ahead of the $573 million expected, adjusted EBITDA improved to $103.6 million from $87.1 million a year earlier, and the EBITDA margin expanded to 17.6 percent. Adjusted EPS of $0.89 beat the $0.81 estimate. The mix is encouraging: Reconstructive grew 11 percent on a reported basis and 6 percent organically, with new products and account conversions driving the pipeline, while Prevention and Recovery held roughly flat, slightly ahead of its market. Enovis describes a portfolio spanning orthopedic bracing, bone-growth stimulators, vascular therapy, and pain-management stimulation alongside its surgical implants (ENOV FY2025 10-K, accession 0001420800-26-000012), a diversified musculoskeletal base that is less cyclical than implants alone.

The valuation gives the turnaround real room. The price sits below the roughly $25.77 book value per share, the asset-based methods cluster near the price rather than above it, and the relative-valuation read on sales lands far higher at about $159 because the company's revenue base of $2.3 billion is large relative to its market value. Management's operating system, which it applies to drive quality, delivery, cost, and innovation (ENOV FY2025 10-K, accession 0001420800-26-000012), is the lever for margin expansion as Lima integrates. The analyst community is unusually bullish, with a consensus near strong buy and an average target in the mid-$40s, roughly double the current price. The bull case is a cash-generative, asset-backed musculoskeletal platform trading below book, where successful integration and steady deleveraging unlock the gap between the equity value and the underlying business.

Bear Case

The bear case is the orthopedic cycle and the leverage that magnifies it. Reconstructive implants, about half the company, ride elective-procedure volumes, and those volumes are sensitive to hospital capacity, staffing, payer pressure, and the broader economic cycle. Enovis competes against far larger, better-capitalized players in hip, knee, and shoulder reconstruction, and the segment's growth depends on continued account conversions in a market where the incumbents defend share aggressively. The Prevention and Recovery segment was essentially flat in the quarter, which tells you the diversified base is not growing fast enough to carry the company on its own. If elective procedure demand softens or pricing tightens, the organic growth that the turnaround needs slows precisely when the balance sheet can least afford it.

That balance sheet is the second and larger problem. Net debt is about $1.29 billion against trailing operating income, and on the reported basis the company is deeply unprofitable, with GAAP operating losses driven by acquisition amortization and impairment. Even on a normalized view the leverage is heavy, and interest coverage near 4.5 times leaves limited slack. The model trips multiple distress signals tied to sustained net-income losses, negative retained earnings, and a weak Altman read, which is why the projection-based valuation methods are floored at zero. The Lima integration carries the assumptions that always accompany a large deal, discount rates, projected net sales, royalty rates, and technology-obsolescence rates baked into the purchase accounting (ENOV FY2025 10-K, accession 0001420800-26-000012), and if those assumptions prove optimistic, further impairment follows. Execution risk on Lima is high and consequential, and the company has limited room for error given the leverage.

The third issue is that the value support is conditional. The stock trades below book, but book value is inflated by acquired goodwill and intangibles that amortize and can impair, so the asset floor is softer than it looks. Trailing return on equity is negative, which means the business is not currently earning its cost of capital, and residual income and earnings-power methods produce no value at all. The relative-valuation read at $159 is a sales-multiple artifact applied because earnings are negative, not a real anchor. The price is supported by asset and multiple value only if the deleveraging works and the margins expand on schedule. Buy it and you are underwriting a leveraged integration into a competitive, cyclical implant market, where the difference between a successful turnaround and a value trap is execution the company has not yet fully proven.

Valuation

Enovis is the rare name in this batch where the price is supported by asset-based and relative-multiple value rather than forward growth, which the characterization makes explicit: a value and asset-supported name, not a pure growth bet. The inversion sits at a degenerate point because the reported operating margin is deeply negative, about negative 47 percent on the GAAP basis, dominated by acquisition amortization and impairment, against an implied long-run margin near 2.3 percent on a normalized read. The mid-cycle margin estimate of about 6.9 percent is the more useful anchor for what the business actually earns once the non-cash charges are stripped out.

The X-ray is shaped by the distress signals. The projection methods, perpetual-growth DCF, exit-multiple DCF, and Peter Lynch, are floored at zero or excluded because of sustained losses, negative retained earnings, and a weak Altman score, so the engine declines to lean on them. What remains is the asset family: the simple excess-return method at about $25.77, which is just book value used as a reference floor, and the two-stage version near $23, both near or slightly above the current price. The relative-valuation method at about $159 is a price-to-sales fallback at 4.0 times revenue applied because EPS is negative, and it is excluded from the consensus for exactly that reason.

The honest synthesis is that this is a balance-sheet-and-cash-flow story, not a multiple story. The trading price below the roughly $25.77 book value, the more than 25 percent free-cash-flow conversion, and the improving adjusted EBITDA margin near 17.6 percent are the real inputs. The bet is that the company deleverages and that the acquired asset base holds its carrying value, in which case the equity is worth more than today's price. The risk is that book value is partly goodwill that can impair and that negative returns on capital persist. The analyst targets in the mid-$40s assume the turnaround works; the asset floor near book is what the price already reflects; the gap between them is the integration and deleveraging execution that has not yet been delivered.

Catalysts

The first-quarter 2026 report was the most recent catalyst and a beat. Revenue rose about 5 percent to $589 million against $573 million expected, adjusted EBITDA improved to $103.6 million with margins expanding to 17.6 percent, and adjusted EPS of $0.89 beat the $0.81 estimate. Reconstructive grew 11 percent reported and 6 percent organically while Prevention and Recovery held roughly flat. Management reaffirmed full-year 2026 guidance of $2.31 billion to $2.37 billion in revenue, $425 million to $435 million in adjusted EBITDA, and $3.52 to $3.73 in adjusted EPS. The next print is a read on whether margin expansion and Recon momentum continue.

The central catalyst is the LimaCorporate integration and the deleveraging it is meant to fund. Management reaffirmed free-cash-flow conversion above 25 percent for 2026, and progress on debt paydown under the revised credit facility is the key thing to monitor, because the equity re-rates as net debt falls. The chief risks are execution missteps on Lima, ongoing negative returns on capital, and limited room for error given the leverage, with tariff and Middle East headwinds noted as pressures management says it can absorb. Analyst sentiment is notably constructive, with a consensus near strong buy and an average target in the mid-$40s, so each quarter of clean integration and deleveraging is a potential catalyst toward closing that gap.

Sources: Investing.com ENOV Q1 2026 margins, StockTitan ENOV Q1 2026, Yahoo Finance Lima integration, StockAnalysis ENOV forecast.

Peer Cohorts (Per Segment, With Filing Citations)

Prevention & Recovery (P&R) (reported)

Reconstructive (Recon) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ENOV report on boothcheck